Navigation Links
Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
Date:1/15/2008

BEVERLY HILLS, Calif., Jan. 15 /PRNewswire/ -- Zetia (ezetimibe) "may not actually prevent heart attacks and strokes," according to the long-awaited results of the Enhance trial. Typically, patients "take Zetia in the form of Vytorin (ezetimibe and simvastatin), which combines Zetia with Zocor (simvastatin)." Zetia and Vytorin are jointly marketed by Merck & Co. and Schering-Plough Corp.

Zetia reduces cholesterol 15 to 20 percent in most patients, no trial has been completed yet that has ever shown that it can reduce heart attacks and strokes -- or even that it reduces the growth of the fatty plaques in arteries that can cause heart problems. The Enhance trial "was designed to show that Zetia could reduce the growth" of fatty plaques in arteries. However, "the plaques actually grew by 0.005 mm more in those taking Zetia along with Zocor than in those taking Zocor alone."

The trial was conducted by a group headed by Dr. John J.P. Kastelein of the University of Amsterdam Medical Center. All 720 participants suffered from an unusual condition known as heterozygous familial hypercholesterolemia. Vytorin cut "LDL levels by 58 percent, compared to a 41 percent reduction with simvastatin alone. However, the researchers found that "the average thickness of the carotid artery plaque increased by 0.0111 of a millimeter in patients taking Vytorin, compared to an increase of 0.0058 of a millimeter in" those taking only simvastatin. According to Dr. Norman Lepor, Westside Medical Associates of Los Angeles and an expert on the treatment of hyperlipidemia, "The complete clinical trial results will be researchers plan to present their data in March at a meeting of the American College of Cardiology." He also said that "one should not confuse the very, very small increase in carotid plaque dimension with a risk of cardiovascular events, as this event data has not yet been presented. Since there do not seem to be any safety issues, there is no urgency to having patients taken off Zetia and replaced with either higher doses of statins, niacin or resins until the full clinical trial results are presented."

Westside Medical Associates of Los Angeles (WMALA) and Westside Medical Imaging (WMI) are premier centers in cardiac diagnosis and treatment.


'/>"/>
SOURCE Westside Medical Associates of Los Angeles
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
2. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
3. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
4. Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis
5. Health Experts and Families Encourage Annual Childhood Flu Vaccination to Reduce Flu-Related Illnesses and Deaths in Children
6. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
7. Smokefree Workplace Law Reduces Heart Attacks 59% Among Nonsmokers, New Research Shows
8. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
Breaking Medicine Technology:
(Date:5/3/2016)... (PRWEB) , ... May 04, 2016 , ... ... for cancer. That message is reaching the global health community through expanding activities ... the burden of cancer in the resource-limited countries. , In support ...
(Date:5/3/2016)... ... May 03, 2016 , ... In April, Amerec launched a new website ... help find the best steam and sauna solutions. , First, the Amerec website has ... improvement brings all of the site’s features, especially the Steam Builder Tool , ...
(Date:5/3/2016)... ... May 03, 2016 , ... For over 23 years, ... providers to build the leading network of doctors and therapists treating personal injury patients ... of the distinguished Bay Chiropractic and Rehabilitation in Santa Monica, Doctors on ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Registration is now open for the 31st ... 5, 2016 at the Hatch Memorial Shell on the Esplanade. The event regularly draws thousands ... 5K Run is a competitive, timed event fully sanctioned by the USA Track & Field ...
(Date:5/3/2016)... Santa Monica, California (PRWEB) , ... May 03, 2016 , ... ... cosmetic surgery practice in late 2014, incorporating the injectable filler into his menu ... journeys of aesthetic transformation. Now, more than a year later, he’s still improving his ...
Breaking Medicine News(10 mins):